Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation

NCT03951961 is registered in ClinicalTrials.gov with University of Jena as lead sponsor.

NCT NCT03951961
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03951961 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Midostaurin in MRD (Minimal Residual Disease) Positive Acute Myeloid Leukemia After Allogeneic Stem Cell Transplantation
Lead sponsor
University of Jena
Phase
Phase 2
Overall status
Terminated
Start date
March 20, 2020
Completion date
February 28, 2021
Enrollment
1 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

acute myeloid leukemia, adult